RT Journal Article
SR Electronic
T1 Recurrence of SARS-CoV-2 PCR positivity in COVID-19 patients: a single center experience and potential implications
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20089573
DO 10.1101/2020.05.06.20089573
A1 Huang, Jia
A1 Zheng, Le
A1 Li, Zhen
A1 Hao, Shiying
A1 Ye, Fangfan
A1 Chen, Jun
A1 Yao, Xiaoming
A1 Liao, Jiayu
A1 Wang, Song
A1 Zeng, Manfei
A1 Qiu, Liping
A1 Cen, Fanlan
A1 Huang, Yajing
A1 Zhu, Tengfei
A1 Xu, Zehui
A1 Ye, Manhua
A1 Yang, Yang
A1 Wang, Guowei
A1 Li, Jinxiu
A1 Wang, Lifei
A1 Qu, Jiuxin
A1 Yuan, Jing
A1 Zheng, Wei
A1 Zhang, Zheng
A1 Li, Chunyang
A1 Whitin, John C.
A1 Tian, Lu
A1 Chubb, Henry
A1 Hwa, Kuo-Yuan
A1 Gans, Hayley A.
A1 Ceresnak, Scott R.
A1 Zhang, Wei
A1 Lu, Ying
A1 Maldonado, Yvonne A.
A1 He, Qing
A1 Wang, Zhaoqin
A1 Liu, Yingxia
A1 McElhinney, Doff B.
A1 Sylvester, Karl G.
A1 Cohen, Harvey J.
A1 Liu, Lei
A1 Ling, Xuefeng B.
YR 2020
UL http://medrxiv.org/content/early/2020/05/10/2020.05.06.20089573.abstract
AB IMPORTANCE How to appropriately care for patients who become PCR-negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still not known. Patients who have recovered from coronavirus disease 2019 (COVID-19) could profoundly impact the health care system if a subset were to be PCR-positive again with reactivated SARS-CoV-2.OBJECTIVE To characterize a single center COVID-19 cohort with and without recurrence of PCR positivity, and develop an algorithm to identify patients at high risk of retest positivity after discharge to inform health care policy and case management decision-making.DESIGN, SETTING, AND PARTICIPANTS A cohort of 414 patients with confirmed SARS-CoV-2 infection, at The Second Affiliated Hospital of Southern University of Science and Technology in Shenzhen, China from January 11 to April 23, 2020.EXPOSURES Polymerase chain reaction (PCR) and IgM-IgG antibody confirmed SARS-CoV-2 infection.MAIN OUTCOMES AND MEASURES Univariable and multivariable statistical analysis of the clinical, laboratory, radiologic image, medical treatment, and clinical course of admission/quarantine/readmission data to develop an algorithm to predict patients at risk of recurrence of PCR positivity.RESULTS 16.7% (95CI: 13.0%-20.3%) patients retest PCR positive 1 to 3 times after discharge, despite being in strict quarantine. The driving factors in the recurrence prediction model included: age, BMI; lowest levels of the blood laboratory tests during hospitalization for cholinesterase, fibrinogen, albumin, prealbumin, calcium, eGFR, creatinine; highest levels of the blood laboratory tests during hospitalization for total bilirubin, lactate dehydrogenase, alkaline phosphatase; the first test results during hospitalization for partial pressure of oxygen, white blood cell and lymphocyte counts, blood procalcitonin; and the first test episodic Ct value and the lowest Ct value of the nasopharyngeal swab RT PCR results. Area under the ROC curve is 0.786.CONCLUSIONS AND RELEVANCE This case series provides clinical characteristics of COVID-19 patients with recurrent PCR positivity, despite strict quarantine, at a 16.7% rate. Use of a recurrence prediction algorithm may identify patients at high risk of PCR retest positivity of SARS-CoV-2 and help modify COVID-19 case management and health policy approaches.Question What are the characteristics, clinical presentations, and outcomes of COVID-19 patients with PCR retest positivity after resolution of the initial infection and consecutive negative tests? Can we identify recovered patients, prior to discharge, at risk of the recurrence of SARS-CoV-2 PCR positivity?Findings In this series of 414 COVID-19 inpatients discharged to a designated quarantine center, 69 retest positive (13 with 2 readmissions, and 3 with 3 readmissions). A multivariable model was developed to predict the risk of the recurrence of SARS-CoV-2 PCR positivity.Meaning Rate and timing of the recurrence of PCR positivity following strict quarantine were characterized. Our prediction algorithm may have implications for COVID-19 clinical treatment, patient management, and health policy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants SZSM201812065 from Sanming Project of Medicine in Shenzhen (Jia Huang); Bill & Melinda Gates Foundations (Lei Liu); and 81501651 from National Natural Science Foundation of China (Jia Huang).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request.